-
Mashup Score: 0Venetoclax Plus ASTX727 Shows Activity in Older, Unfit Patients With AML - Oncology Nurse Advisor - 2 month(s) ago
Venetoclax plus ASTX727 demonstrated safety and efficacy in patients with AML who were older or ineligible for intensive chemotherapy, according to researchers.
Source: www.oncologynurseadvisor.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 6
PURPOSE A prospective phase II study examined the safety and efficacy of venetoclax combined with low-dose cytarabine (LDAC) in AML at first measurable residual disease (MRD) or oligoblastic relapse. METHODS Patients with either MRD (≥1 log10 rise) or oligoblastic relapse (blasts 5%-15%) received venetoclax 600 mg once daily D1-28 plus LDAC once daily D1-10 in 28-day cycles. The primary objective was MRD response in the MRD relapse cohort or complete remission (CR/CRh/CRi) in the oligoblastic relapse cohort. RESULTS Forty-eight adults with either MRD (n = 26) or oligoblastic (n = 22) relapse were enrolled. Median age was 67 years (range, 18-80) and 94% had received previous intensive chemotherapy. Patients received a median of four cycles of therapy; 17% completed ≥12 cycles. Patients with oligoblastic relapse had more grade ≥3 anemia (32% v 4%; P = .02) and infections (36% v 8%; P = .03), whereas grade 4 neutropenia (32 v 23%) or thrombocytopenia (27 v 15%) were comparable with the MR
Source: ascopubs.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5
PURPOSE Magrolimab is a first-in-class humanized monoclonal antibody against cluster of differentiation 47, an antiphagocytic signal used by cancer cells to evade phagocytosis. Azacitidine upregulates prophagocytic signals on AML cells, further increasing phagocytosis when combined with magrolimab. We report final phase Ib data for magrolimab with azacitidine in patients with untreated AML ineligible for intensive chemotherapy (ClinicalTrials.gov identifier: NCT03248479). PATIENTS AND METHODS Patients with previously untreated AML, including TP53-mutant AML, received magrolimab intravenously as an initial dose (1 mg/kg, days 1 and 4), followed by 15 mg/kg once on day 8 and 30 mg/kg once weekly or every 2 weeks as maintenance. Azacitidine 75 mg/m2 was administered intravenously/subcutaneously once daily on days 1-7 of each 28-day cycle. Primary end points were safety/tolerability and proportion with complete remission (CR). RESULTS Eighty-seven patients were enrolled and treated; 72 (82
Source: ascopubs.orgCategories: General Medicine News, Onc News and JournalsTweet
A regimen consisting of venetoclax and ASTX727 demonstrated safety and efficacy in patients with #acuteMyeloidLeukemia who were older or ineligible for intensive chemotherapy, according to researchers. Reported in @TheLancetHaem. https://t.co/s4vYZ4V6GP #AML #leusm